Skip to content
TrackPodcasts
businessFeb 3, 20261:00:43pending

The Glucose Sensor That Predicts the Future with Mark Tapsak

About this episode

In this episode, Henry Norton sits down with Mark Tapsak, Chief Science Officer at Glucotrack and one of Dexcom's earliest employees.

Mark Tapsak left Medtronic for a "crazy startup" called Dexcom after seeing data so compelling he couldn't say no. Two decades later, he's back in the CGM game as Chief Science Officer at Glucotrack, working on a 3-year implantable sensor that lives in the bloodstream.

Key Topics:

  • Mark's path from blue-collar Minnesota to polymer chemistry PhD

  • The founding days of Dexcom and the "three fathers" of CGM (Goff, Updike, Heller)

  • Why early CGM struggled to convince endocrinologists of continuous data's value

  • Dexcom's pivot from implantable to short-term sensors

  • Glucotrack's evolution from non-invasive ear clip to intravascular 3-year sensor

  • Current trial progress in Brazil and Australia, and the path to US IDE

Related Insights:

  • Why implanting devices in the body is "harder than going to the moon"

  • The business case for long-term implantables vs. wearables

  • How the immune response creates a "sleep period" that tanks glucose signals

  • Why timing and market readiness matter as much as technology

Core Challenges:

  • Early CGM implantables worked in only ~50% of patients, forcing a pivot to wearables and delaying long-term solutions by decades.

  • Glucotrack is now targeting a 3-year intravascular sensor that bypasses the aggressive subcutaneous immune response, with US trials expected in 2026.

🎧 Tune in now to hear how CGM went from academic curiosity to medical device success story, and what comes next.


The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.


To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠


A big thank you to our sponsors on this season of the podcast;


⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠


Get every episode summarized

Each time The Crux of Medtech publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.

Email me new episodes

Free for 3 shows. No card needed.

Hosts & guests

No transcript yet

This episode has not been transcribed. Request it and it moves to the front of the queue.

The Glucose Sensor That Predicts the Future with Mark Tapsak

The Crux of Medtech

0:00
1:00:43

More episodes

More from The Crux of Medtech

View all episodes →